Cephalon earnings fall short on costs, revenues; Sun gets FDA approval for Taxotere copy;

@FiercePharma: Pfizer profits beat, but drug sales drop. Report | Follow @FiercePharma

> Cephalon, which agreed this week to be bought by Teva Pharmaceutical Industries, reported lower-than-expected first-quarter earnings as costs jumped 37 percent and revenue fell short of Wall Street estimates. Article

> Actelion said it will appeal against the final U.S. jury verdict that awarded Asahi Kasei Pharma Corp. (AHKSY) compensatory damages of up to $547 million and punitive damages of $30 million. Story

> Sun Pharmaceutical got the FDA nod for its anti-cancer drug Docefrez (Docetaxel), a generic version of Sanofi-Aventis' Taxotere. Article

> Pfizer's Pristiq, a follow-up to the antidepressant Effexor, proved effective at reducing hot flashes in a 12-week sub-study of post-menopausal women. News

> Hikma Pharmaceuticals has completed its $112 million acquisition of Baxter Healthcare Corporation's US generic injectables business. Report

> Perrigo beat the analysts' revenue and earnings per share consensus for the third fiscal quarter of 2011, and raised its full-year guidance. News

> FDA and the Federal Trade Commission announced a joint effort to remove products from the market that make unproven claims to treat, cure, and prevent sexually transmitted diseases. Article

> Sales of drugs to treat non-Hodgkin's lymphoma are set to more than double in value over the next decade, increasing in seven major world markets to $8.4 billion by 2019. Item

> Pharmaceutical wholesaler McKesson posted a higher quarterly profit driven by strong results in its U.S. operations and profit growth in generic drugs. Item

> Vertex Pharmaceuticals reported a wider loss, due to costs of preparing to launch its closely watched treatment for hepatitis C. Story

Biotech News

 @FierceBiotech: Clinical, regulatory jobs top biotech's "must-hire" list. News | Follow @FierceBiotech

 @JohnCFierce: Every time a biotech gets back a partnered program, it's positioned as a big win. That sometimes happens (Exelixis), but it's no easy task. | Follow @JohnCFierce

> Onyx bows out of $550M JAK2 collaboration with S*BIO. Report

> Valeant CEO scanning biopharma horizon for fresh targets. Article

> Allergan snags rights to retinal disease drug in $420M pact. News

> Bayer CEO sketches the perfect takeover target. Item

> Yale signs up for another drug discovery deal. Item

Drug Delivery News

> Nanovaults deliver drugs that kick-start the immune system against lung cancer. News

> India's Manipal College prepares for nanotech drug-delivery revolution. Story

> MicroDose's dry powder inhaler incorporated into Novartis device. Story

> MIT nanoparticle peels away layers of tumor entry. Article

> Thai researchers test brain cancer delivery system. Report

Medical Device News

> Boston Scientific alerts public about stolen shipment. Story

> Databases track patients with artificial knees, hips. Report

> NeuroVigil closes first round of financing. Item

> Nanostim signs investment deal with St. Jude. Article

> Baucus questions Medtronic over GPO contract cancellations. News

> Mazor gets good news in Europe on SpineAssist. Article

> Gene-therapy approach appears to work for AMD drug. Article

And Finally... Record numbers of American have asthma, with nearly one in 10 children and almost one in 12 Americans of all ages suffering from the condition, according to a study released by the Centers for Disease Control and Prevention. Report

Suggested Articles

German viral vector CDMO Vibalogics has hired Lonza veteran Tom Hochuli as global CEO to help lead its U.S. expansion efforts.

Merck’s Keytruda already boasts an OK in some esophageal cancer patients, but it’s looking to widen its reach in the tough-to-treat disease.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.